The NAP motif of activity-dependent neuroprotective protein (ADNP) enhanced memory scores in patients suffering from mild cognitive impairment and protected activities of daily living in schizophrenia patients, while fortifying microtubule (MT)-dependent axonal transport, in mice and flies. The question is how does NAP fortify MTs? Our sequence analysis identified the MT end-binding protein (EB1)-interacting motif SxIP (SIP, Ser-Ile-Pro) in ADNP/NAP and showed specific SxIP binding sites in all members of the EB protein family (EB1-3). Others found that EB1 enhancement of neurite outgrowth is attenuated by EB2, while EB3 interacts with postsynaptic density protein 95 (PSD-95) to modulate dendritic plasticity. Here, NAP increased PSD-95 expression in dendritic spines, which was inhibited by EB3 silencing. EB1 or EB3, but not EB2 silencing inhibited NAP-mediated cell protection, which reflected NAP binding specificity. NAPVSKIPQ (SxIP = SKIP), but not NAPVAAAAQ mimicked NAP activity. ADNP, essential for neuronal differentiation and brain formation in mouse, a member of the SWI/SNF chromatin remodeling complex and a major protein mutated in autism and deregulated in schizophrenia in men, showed similar EB interactions, which were enhanced by NAP treatment. The newly identified shared MT target of NAP/ADNP is directly implicated in synaptic plasticity, explaining the breadth and efficiency of neuroprotective/neurotrophic capacities.
INTRODUCTION
Activity-dependent neuroprotective protein (ADNP), 1,2 mutated in ≥0.17% of autism spectrum disorder cases (one of the most frequent autism spectrum disorder-associated genes known todate), 3 deregulated in schizophrenia, 4, 5 predicting the onset of frontotemporal dementia 6 and identified by complete proteomics as the only protein significantly decreasing in Alzheimer's disease (AD) patient serum (compared with matched controls), 7 takes part in chromatin remodeling as a component of the essential SWItch/ sucrose nonfermentable (SWI/SNF) complex. 8, 9 While regulating 4400 genes during embryonic development, [10] [11] [12] ADNP is not confined to the cell nucleus, [13] [14] [15] and interacts with key regulators of the autophagy process, linked to cytoplasmic microtubules (MTs). 5 MTs, key cytoskeletal filaments found in all eukaryotic cells, provide structural support, segregation of chromosomes and intracellular trafficking. Neuronal MTs are essential for axonal transport and synaptic transmission. 16, 17 MT +end tracking proteins (+TIPs), including end-binding proteins (EBs), have a role in axonal outgrowth and interact with MT-associated proteins. 18 Of the three mammalian EB family members (EB1, EB2 and EB3), 19 EB3 is preferentially expressed in the brain and is used to track MT dynamics. 20, 21 Although present in axons and growth cones, EB3 is predominantly localized within the dendritic compartment and has been characterized as a major regulator of dendritic spine plasticity by influencing actin dynamics within the spine. [22] [23] [24] EB1, sharing 54% identity with EB3, has been implicated in axonal transport. 23 EB1/EB3, but not EB2 promote persistent MT growth by suppressing catastrophes, 25 increase neurite number in pheochromocytoma (PC12) cells, while EB2 blocks neurite elongation, 26 attenuating EB1 activity. 27 EB2 does not form dimers with either EB1 or EB3, while EB1/3 dimerization (but not necessarily heterodimerization) is a prerequisite for +TIP partner binding. 28, 29 The short peptide motif, Ser-x-Ile-Pro (SxIP) is used by numerous +TIPs for localization to MT tips in an EB1-dependent manner, 30 and EB3 has also been suggested to interact with this motif, for example in plexin. 31 EB3 binds directly to p140Cap (Src kinase signaling inhibitor1, SRCN1, containing an SIP motif). Localized at the postsynaptic density, 24 p140Cap interacts with synaptosomal-associated protein of 25 kDa (SNAP-25) to regulate spine formation. 32 Structure activity mapping of ADNP fragments identified NAP (NAPVSIPQ), containing a SIP motif, as a neuroprotective peptide. 1 In AD models, NAP protected against MT-associated tau pathology and cognitive decline. [33] [34] [35] NAP treatment regulated the MT cellular pool, affecting MT dynamics/stability in neuronal and glial cells, which was associated with dynamic MT invasion into the growth cone and enlisting of tau to the MT shaft under stress conditions 36 as well as protecting against MT severing in the face of tau depletion. 37 Similarly, NAP recovered axonal transport in vivo, after MT breakdown by colchicine, protected against axonal transport disruption in an amyotrophic lateral sclerosis mouse model exhibiting tau pathology 38 and in a Drosophila model expressing abnormal human tau. 39 In patients presenting mild cognitive impairment (preceding AD and having tau pathology), NAP (davunetide) significantly protected verbal recall and visual working memory. 40 Furthermore, NAP treatment enhanced activities of daily living 41 and provided prefrontal cortex protection (as measured by magnetic resonance spectroscopy evaluating Nacetylaspartate and choline levels) 42 in schizophrenia clinical trials. Here, we set out to identify whether the SIP motif governs NAP's neurotrophic/neuroprotective activities through interaction with EB3 and EB1, with an eye toward better understanding of its molecular and cellular activities, as an active motif and a prototype drug candidate derived from an essential protein.
MATERIALS AND METHODS Peptides
Peptides were purchased from Hy-Labs (Rehovot, Israel). NAP (NAPVSIPQ), generic name, davunetide was from Allon Therapeutics (Vancouver, BC, Canada).
Recombinant EBs
Human EB3 (pEX-N-His Vector; OriGene, Rockville, MD) was subcloned into pEX-N-His vector (PrecisionShuttle bacterial expression vector with N-terminal His tag CW300309, OriGene). Competent Escherichia coli BL-21 Tuner (Novagen, Darmstadt, Germany) cells were transformed with the vector on LB agar plates containing 100 μg ml -1 ampicillin and 34 μg ml -1 chloramphenicol. Transformed cells were grown (3-4 h, 37°C, LB+antibiotics). Temperature was lowered to 16°C upon reaching 0.25OD/600 nm. Protein expression was induced with 250 μM IPTG when the culture reached 0.6OD. Bacteria were harvested after 14 h by centrifugation and stored at − 80°C. The N-terminal 6xHis-tagged fusion proteins were purified by affinity chromatography on Ni 2+ -Sepharose (GE Healthcare, Uppsala, Sweden) at 4°C . Proteins were filtered on a Superdex200 column (GE Healthcare) equilibrated in 20 mM Tris-HCl (pH 7.5), supplemented with 75 mM NaCl.
Recombinant EB1 and EB2 were obtained from human brain cDNA 4 by PCR (Supplementary Table S1a ). The required PCR fragments were isolated from 0.8% agarose gels with Wizard ® SV Gel and PCR Clean Up System (Promega, Fitchburg, WI, USA) and cloned using the restriction enzymes, XhoI and HindIII (New England Biolabs, Ipswich, MA, USA), T4 DNA ligase and pET28a-MBP-TEV-a modified pET28a (Novagen) vector, in which maltose binding protein (MBP) followed by a Tobacco Etch virus (TEV) cleavage site were engineered downstream the 6xHis tag site, between the NdeI and BamHI restriction sites. Transformation, protein preparation and purification were done as described for EB3 with the exceptions of substitution of ampicillin with 50 μg ml -1 kanamycin, cleavage of 6xHis-tag-MBP by TEV protease, X2 Ni 2+ -Sepharose purification. Proteins were quantified using the BCA TM Protein Assay Kit (Pierce, Rockford, IL, USA).
NAP affinity chromatography
Column included SulfoLink ® Immobilization Kit (agarose beads) for Peptides (Pierce) conjugated to CKKKGGNAPVSIPQ or CKKKGGNAPVKSIP as before. 43, 44 Immunoprecipitation Proteins were extracted from ADNP expressing P19 cells 11 (Supplementary Materials and Methods). The Co-IP kit (Pierce) was used with 30 μl of A/G PLUS-agarose beads/cross-linked to 10 μg of (1) 
Primary neuronal cultures
Newborn rats were killed on postnatal day 1 and enriched neuronal cultures were obtained and maintained as before 36 (Supplementary Materials).
PC12
Cells (ATCC, Bethesda, MD, USA) were grown and maintained as before 36 (Supplementary Materials).
COS-7 cells
COS-7 cells (ATCC, CRL-1651) were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum and 100 U ml 
Neuronal immunostaining
Cells were fixed and permeabilized simultaneously, with 3% paraformaldehyde, 0.075% glutaraldehyde (Fluka Biochemika, Sigma, Rehovot, Israel) in MT buffer (80 mM PIPES pH6.8, 1 mM MgCl 2 , 2 mM EGTA, 5% Glycerol) with 0.5% Triton X-100 (10 min), quenched with 1 mg ml -1 NaBH 4 in PBS, or fixed with ice-cold methanol, blocked with 2% BSA and 5% normal goat serum in TBS-T (20 mM Tris pH7.5, 136.8 mM NaCl, and 0.05% v/v Tween-20), and incubated with primary antibodies followed by the appropriate secondary antibodies. Nuclei were visualized with Hoechst dye.
Confocal microscopy and image analysis
Images were collected with a Leica SP5 confocal laser scanning microscope (Mannheim, Germany) with x63 (NA1.4) oil immersion optics, laser lines at 488, 561 and 633 nm and analysis was performed as before. 36 
RNA silencing
RNA silencing was performed as before 12 and the specific protocol is outlined in the Supplementary Materials. , ATCC, passage #20) were used. One day before transfection, cells were seeded onto 96-well plates in 100μl growth medium/well without antibiotics at a concentration of 5 × 10 3 cells/well, such that they were 30-50% confluent at the time of transfection. In all, 50 nM of each siRNA construct was used. The medium was changed 6 h after transfection. In all, 72 h later, cells were harvested to assay for gene knockdown or subjected to Zn toxicity for 4 h at 37°C and 5% CO 2 . Survival was measured using the non-radioactive cell proliferation assay (MTS) assay for metabolic activity of cells using the CellTiter96 ® Aqueous NonRadioactive Cell Proliferation kit (Promega).
Polymerized vs soluble tubulin separation assay
These assays were performed as before. 36 
Statistical analysis
Data are presented as the mean ± s.e.m. from ≥3 independent experiments performed in (1) 
RESULTS

ADNP/NAP binds EB3
Comparative sequence analysis showed that the main (SxIP) motifinteracting residues are highly conserved among EBs, while other residues involved in the cavity (likely to have interactions with the other residues of the binding peptide) are less conserved, especially in EB2 (Supplementary Figure S1 ). As expected, EB3 was highly expressed in neuronal cell cultures (Supplementary Figure S2 ). To assess whether the NAP (NAPVSIPQ)-containing parent protein, ADNP, interacts with EBs, immunoprecipitation (IP) with protein extracts from the original ADNP source, P19 cells, was employed. P19 cells also express EBs (Supplementary Figure S2) . 27 ADNP IP identified an EB1-like immunoreactive band (IB) on western blots (Figure 1a ), but not EB2 or EB3 (Figures 1b and c) . However, when EB2 or EB3 antibodies were used for IP, interaction with ADNP-like IB was observed as well ( Figure 1d ). The strong~50 kDa IB band seen in ADNP-EB IP (Figures 1a and c) was suspected to be the MT subunit, tubulin, and specific tubulin IP resulted in ADNP-IB (Figure 1e ). This was verified by IP with ADNP antibodies (Figure 1f ). When ADNP IP was performed in the presence of NAP, an additional tubulin-IB appeared with a molecular weight identical to EB3 (Figure 1f) . Similar results were obtained with p140Cap IB, an EB3-interacting molecule. 24 Further IB showed that the tubulin (TUB2.1) and the p140Cap antibodies also identified recombinant EB3 ( Figure 1h ). As NAP is not part of the epitope recognized by the ADNP antibody used for the IP (Figure 1f) , we conclude that NAP enhanced ADNP-EB3-p140Cap interaction.
The direct interaction of NAP with EB3 was tested using affinity chromatography. Recombinant human EB3 was incubated with extended NAP (CKKKGGNAPVSIPQ) covalently linked to agarose beads. Load, flow through, wash and elution fractions were separated by PAGE, followed by IB with EB3 antibodies. The results identified NAP-EB3 binding (Figure 2a) . Column specificity was shown by competition with NAPVSIPQ/EB3-mimetic peptides (which did not contain the CKKKGG spacer used to avoid steric hindrance; see Supplementary Figure S3 ). Thus, NAP-linked beads were incubated with recombinant EB3 and either: (1) soluble NAP (positive control, which should displace all binding); (2) NAPVS-KIPQ (representing a potential EB3 binding, NAP mimetic); (3) NAPVSAIPQ, a potential closely related negative control; and (4) NAPVAAAAQ, a negative control which does not contain an EB3-binding signature. Competition with NAP or NAPVSKIPQ, inhibited EB3 binding to the NAP-affinity column. Contrarily, no competition was apparent with NAPVSAIPQ or NAPVAAAAQ; EB3 was bound to NAP and specifically eluted at acidic concentrations (Figure 2b ). To verify that EB3 was indeed specifically bound and eluted from the NAP column in the presence of NAPVAAAAQ, beads were taken from the column resin, mixed with sample buffer, and western blot analysis was performed indicating no EB3 binding to the resin itself (Figure 2b , 'AAAA'-beads lane). Thus, EB3 is a direct binding target for NAP and its interaction is mediated by the SxIP binding motif, SIP or SKIP.
To verify these results and assess possible binding to all EBs, we incubated each one of the three recombinant EBs (EB1-3) with NAP beads. We have also inserted another measure of specificity, namely column pre-incubation with BSA. While EB1 and EB3 interacted with immobilized NAP, essentially, no NAP-EB2 binding was observed (Figure 2c ). To further ascertain specificity, we have added another affinity column with CKKKGGNAPVSKIP and our results showed specific binding of NAPVSKIP to EB1 and EB3 (Figure 2d ).
To evaluate interaction at the cellular level, we ectopically expressed the EB3 protein tagged with RFP-EB3 in COS-7 cells (Figure 3 ,~1000 cells were evaluated, showing~2% transfection efficiency). Immunofluorescence with far-red labeled tubulin antibodies assessed MT localization. Labeled EB3 co-localized with tubulin/MTs (Figure 3a) . Furthermore, 6-fam-NAP was seen within the non-transfected cell, as before 43 ( Figure 3a) . Next, 6-fam-NAP was added to the EB3-transfected cells. As seen in Figure 3b , tubulin, EB3 and NAP were co-localized and showed a classical fibrous cellular organization. Analysis of only two individual labels at a time (in the presence of 10 − 12 M NAP) indicated co-localization of tubulin with EB3, NAP with tubulin, and NAP with EB3 (Figure 3c ). NAP and EB3 cellular localization was ascertained by nuclear labeling (Figure 3d, blue) , specificity for EB3 apparent reorganization in the presence of NAP was ascertained in the absence of nuclear labeling (Figure 3d Figure S2) . Previously, EB3 knockdown significantly reduced the number of spines (∼60% of control) without altering spine morphology when incubated for 1 week. 46 Shorter exposure times (4 days) showed morphological changes, but no effect on the number of protrusions after EB3 silencing. 24 Given the observed NAP-EB3 interaction and NAP effects on MT organization in primary cortical neurons, 36 we asked whether NAP affects dendritic spines in these neurons and whether this effect required EB3. We used PSD-95 immunoreactivity, as a spine measure. 47 Incubation of primary cortical neurons with NAP (2 h) increased the number of PSD-95 puncta per length of the dendritic shaft (Figures 4a and b, green dots) . A bell-shaped dose response curve was observed with a highly significant peak at 10 − 12 M NAP (Figure 4c ). The EB1/EB3 binding NAPVSKIPQ mimicked NAP activity. NAPVSAIPQ and NAPVAAAAQ (non-competing for EB3-NAP binding) did not enhance PSD-95 puncta density (Figure 4d) . Silencing of EB3 mRNA (48 h, Supplementary Figure S2) , while not reducing PSD-95 puncta density (Figure 4e) , significantly reduced the individual stained puncta area (Figure 4f ) and inhibited NAP activity, on both puncta density and the individual puncta stained area which was significantly increased by 25% in the presence of NAP (Figure 4f) . Unlike NAP, which increased the individual puncta stained area, the NAP-mimetic which does not bind EB3, NAPVAAAAQ, did not increase the individual puncta stained area (Supplementary Figure S4) , indicating specificity.
NAP cellular protection requires EB1 or EB3, but does not require EB2 To extend the EB dependence of NAP activity, PC12 cell EBs were each subjected to RNA silencing and NAP activity was evaluated by MTS. To ascertain knockdown, cell extracts were subjected to RNA or western analysis (Supplementary Figure S2 and S5) . Silencing EBs resulted in at least 50% reduction in expression of the respective transcript/protein. To further assess NAP protection, we have used Zn toxicity for the following reasons. (1) High Zn concentration disrupts MTs, which is reversed by NAP in neurons, 44 glia 43 and PC12 cells. 36 (2) Toxic Zn induces a Src family kinase-mediated upregulation of N-methyl-D-aspartate (NMDA) receptor (NMDAR) activity excitotoxicity 48 and neurodegeneration (the EC50 for Zn cell killing is at 308+38 μM 36 ).
Accordingly, we have added Zn (400 μM) to PC12 cells which resulted in 30-50% death (Figure 5a ). In all, 10 -12 M NAP's partial but significant protection against Zn intoxication was completely abolished by EB1 or EB3 but not by EB2 silencing. Thus, NAP requires intact EB1/EB3 expression for cellular protection.
Further evaluation of 10 − 9 M NAP and peptide derivatives together with 400 μM Zn showed that NAPVSKIPQ and acetyl-NAPVSKIPQ-NH 2 provided protection against Zn toxicity, mimicking NAP's activity (Figure 5b ). In contrast, NAPVSRIPQ and NAPVTRIPQ were inactive ( Figure 5c ).
As Fyn was previously shown to be essential for NAP activity on axonal growth, 49 we have also tested whether Fyn-MT interaction was altered following EB silencing. Results showed~2-fold decreased Fyn-MT interaction following EB1 silencing, suggesting an involvement of Fyn in the NAP signaling cascade, downstream of EB1 (Figure 5d ). ] and eluted antigen was identified by 8% PAGE and IB with rabbit ADNP antibody. (f) Cell extracts (500 μg) were precipitated with 10 μg ADNP antibody or (g) in the absence or in the presence of 3 mg NAP. Tubulin was detected by TUB2.1 and p140Cap, by a p140Cap antibody. C = control extract, E = elution. (h) Recombinant EB3 was subjected to NAP affinity column and blots ( Figure 2) were subjected to TUB2.1 IB or p140Cap antibody (1:500 dilution). EB, end-binding protein.
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DISCUSSION
Our original affinity chromatographies with total brain extracts suggested tubulin as an NAP-associating partner. 43 We now propose that this interaction is largely through direct NAP-EB1/EB3 binding. We posit a mechanism of action for NAP that invokes protein cooperation, including ADNP, at the growing MT tip, ultimately leading to neurotrophism (Figure 5e ) and protection against dysfunction/cognitive deficiencies (for example, in ADNP +/ − mice, spared by NAP replacement 35 ). ADNP may also bind EB2, which could be connected to other epitopes of the large molecule. ADNP, 1 essential for brain formation, 10 affecting brain development, 8, 11, 14 brain injury protection 50 and aging, 35 is now linked to EB1/EB3 through the NAP active site mediating MT neuroplasticity, including the autophagy pathway. 5, 51 EB dimerization is a prerequisite for +TIP partner binding. 28 The affinity of individual +TIP-EB1 interactions is weak (low μM) and multiple SxIP motifs cooperate to increase the EB-dependent targeting efficiency 30 (for example, EB1 and CLIP-170 synergistically regulate MT dynamics 52 ). We suggest that NAP potency is associated with this cooperative effect (Figure 5e ).
Initial observations also included an~100 kDa NAP-interacting protein, 43 which when subjected to mass spectrometry was identified as drebrin, an EB3-binding protein essential for neuritogenesis 22 and our current results discovered a p140Cap-ADNP interaction, probably indicative of the cooperative association with EBs (Figure 4e) .
The neuronal/astrocyte enriched p140Cap (containing the NAPlike SIP motif) binds (1) EB3, (2) SNAP-25 and (3) the scaffold protein p130Cas, negatively regulating Src kinase through the activation of Csk kinase. 53 NAP-related increase in SNAP-25 and synaptophysin during development and protection against depletion of synaptophysin under stress 54, 55 are now tied to EB1/EB3-binding increasing neurite outgrowth and EB3-related spine plasticity.
NAP discovery included screening for neuroprotection against tetrodotxin (TTX) electrical blockade.
1 Ala scanning substitution of NAP showed that its SIP motif is crucial for protection of cortical neurons against TTX. 56 When chronically exposed to TTX, cortical neurons lose dendritic spines, and degenerate. 57 Thus, NAP may protect against TTX-associated dendritic spine lose. Indeed, in cortical neurons co-cultured with prenatal ethanol exposed astrocytes, exhibiting a reduction in dendrite number than neurons seeded on control glia (which expressed higher levels of ADNP), NAP significantly increased dendritic growth. Similar effects were observed on axon growth/branching. 54 The SH3 domain of PSD-95 directly binds to a polyproline-rich region of EB3 to alter MT dynamics, at the level of dendritic plasticity.
58 EB3 controls actin dynamics and regulates spine morphology/synaptic plasticity, through interaction with PSD-95, and NMDAR activation. 59 In this respect, NAP (also interacting with actin, 43 probably through EB3) protected against NMDA excitotoxicity and accelerated neurite outgrowth 60 /neurodevelopment. 1 NAP-induced axon growth requires Fyn kinase. 49 Fyn, a member of the SFKs (Src non-receptor tyrosine family kinases), 61 organizes the postsynaptic machinery by NMDAR phosphorylation, 62 thereby increasing its affinity to PSD-95. 63, 64 Exposure of neurons to Zn upregulates NMDAR cytotoxicity via activation of SFKs. Fyn binds tau 65 and tau is phosphorylated by SFKs. 61 When tau detaches from the MTs upon phosphorylation, it can access the dendritic compartment, thereby increasing Fyn concentration and Figure 2 . EB3 binds to NAP (NAPVSIPQ) and to SKIP (NAPVSKIPQ). NAP was bound to sulfolink coupling resin and recombinant EB3 was loaded on the resulting affinity column. Proteins were separated by sodium dodecyl sulfate (SDS)-10% polyacrylamide gel electrophoresis (PAGE) followed by immunoblot (IB). Molecular weight was determined with markers. The figure shows the IB results for EB3 antibodies (32 kDa; a and b). Experimental points were repeated ≥2. consequently NMDAR phosphorylation. In Tau − / − cells, Fyn is excluded from the dendrites, and expression of a truncated tau mutant that is excluded from the dendrites leads to sequestration of Fyn in the soma. 66 Fyn − / − mice exhibited decreased spine density and abnormal spine morphology in an age-dependent manner. 67 Integration of chemical and electrical information involving NMDAR is crucial for activity-dependent synaptic plasticity underlying neuronal development and memory formation. 68 In contrast, dysfunction of NMDARs is implicated in numerous brain diseases, including AD, and schizophrenia. 69 In the hippocampus and prefrontal cortex, the physiological upregulation of NMDAR by Src is blocked by neuregulin1-ErbB4 signaling, a pathway that is genetically implicated in schizophrenia. 70 NMDAR activation induces sustained alterations in the MT network and EB3 localization in dendrites and further suppresses MT entry into dendritic spines.
We propose that NAP binds to EB3/EB1 and promotes other SxIP-containing proteins like ADNP (Figure 1 ), to interact with EBs ( Figure 5e ) thereby enhancing MTs impact on neuroplasticity and neuroprotection. Together, this mechanism can explain the high potency of NAP, amplifying the MTs +TIPS, as well as the bellshaped dose response curve (for example, Figure 4c ), associated with crowding at the growing MT end. The interaction with EB could also explain the previously described NAP association with tubulin/MT, 43, 44 enlisting of tau to MTs, 36 protecting against tauopathy 39 and tau depletion, 37 as well as cellular specificity lack of an effect on cancer cells, which may be expressing EB2. 71 Furthermore, spectraplakins promote MT-mediated axonal growth by functioning as structural MT-associated proteins and EB1-dependent +TIPs through an SxIP motif, suggesting that NAP effect on neurite outgrowth, the growth cone and axonal transport may be explained by interaction with EB1/EB3. 72 The association with the EB3-interacting drebrin is of importance to maintain proper development and synaptic plasticity 22 and may be constitute another clinical target given drebrin's decrease in the cortex of Down's syndrome and in AD patients. 73 In this respect, NAP treatment protects Down's syndrome neurons 74 and mild cognitive impairment. 40 Interestingly, PSD-95 is significantly decreased in the prefrontal cortex of schizophrenia patients 75 and NAP (davunetide) treatment protected activities of daily living 41 and provided prefrontal cortex protection 42 in schizophrenia clinical trials. The essential role of ADNP in brain formation and function and NAP efficacy in human clinical trials are now coupled to the understanding of the cellular mechanism of action. NAP, the EBinteracting motif of ADNP, is proposed as a first class drug candidate, paving the path to the discovery of novel ways (including the newly discovered NAPVSKIPQ) to combat devastating brain disorders associated with the loss of vital cellular functions which culminate in loss of crucial daily activities.
